PSNLPersonalis, Inc.

NAS · US · Healthcare · Diagnostics & Research · personalis.com

18.38USD+16.26%Mkt Cap: 1.96B $P/E: —3d ago

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of mi…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

$44.91BUSDP/E 31.9

IDXX

IDEXX Laboratories, Inc.

Mettler-Toledo International, Inc.

$27.96BUSDP/E 31.5

Labcorp Holdings Inc.

$27.28BUSDP/E 27.8

DGX

Quest Diagnostics Incorporated

$26.97BUSDP/E 26.0

Guardant Health, Inc.

$22.91BUSD

MEDP

Medpace Holdings, Inc.

$17.33BUSDP/E 36.4

ERF

Eurofins Scientific SE

$13.65BUSDP/E 25.3

CRL

Charles River Laboratories International, Inc.

$14.09BUSD

RVTY

Revvity Inc. Common Stock

$13.92BUSDP/E 59.7

ICLR

ICON Public Limited Company

Twist Bioscience Corp.

$9.13BUSD

Key Statistics

Company

Market Cap1.96B $

Enterprise Value1.63B $

Revenue (TTM)69.67M $

Gross Profit15.78M $

Net Income (TTM)-81.27M $

Revenue/Share0.7130 USD

Last Price18.38 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees259

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-17.93

PEG—

EV/EBITDA-15.57

EV/Revenue23.37

P/S25.88

P/B7.63

EPS (TTM)-1.17

EPS (Forward)-0.94

52W Range

4.44096% of range18.89

52W High18.89 USD

52W Low4.440 USD

Profitability

Gross Margin22.65%

Oper. Margin-150.25%

EBITDA Margin-150.13%

Profit Margin-116.69%

ROE-31.12%

ROA-24.32%

Growth

Revenue Growth30.00%

Earnings Growth—

Cash Flow & Leverage

Operating CF-74.95M $

CapEx (TTM)4.50M $

FCF Margin-80.42%

FCF Yield-2.86%

Net Debt-174.66M $

Net Debt/EBITDA1.67

Balance Sheet

Debt/Equity0.15

Current Ratio5.28

Quick Ratio4.91

Book Value/Sh2.211 USD

Cash/Share1.991 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.8 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)13.88 USD

Upside (mean)-24.5%

Target Range10.00 USD – 16.25 USD

$10.00-24.5% to mean$16.25

# Analysts4

Ownership

Shares Out.106.75M

Float72.33M

Insiders26.15%

Institutions66.67%

Short Interest

Short Ratio1.7d

Short % Float12.74%

Short % Out.8.16%

Shares Short8.71M

Short (prev mo.)11.31M

Technical

SMA 5013.02 (+41.2%)

SMA 2009.381 (+95.9%)

Beta2.29

S&P 52W Chg18.16%

Avg Vol (30d)4.40M

Avg Vol (10d)3.90M

Technical Indicators

RSI (14)76.1

MACD0.8450

MACD Signal0.4944

MACD Hist.+0.3506

BB Upper16.73 USD

BB Middle13.56 USD

BB Lower10.39 USD

BB Width46.76%

ATR (14)1.025 USD

Vol Ratio (20d)2.76x